Detalhe da pesquisa
1.
At-home asthma mortality unchanged despite declining mortality in other settings: US death certificate data (2000-2019).
Ann Allergy Asthma Immunol;
132(2): 216-222, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37848103
2.
Geographic variation in disease burden among patients with severe persistent asthma in the United States.
Ann Allergy Asthma Immunol;
132(5): 602-609.e4, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38141810
3.
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Am J Respir Crit Care Med;
208(1): 13-24, 2023 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37015033
4.
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
Clin Exp Allergy;
53(4): 417-428, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36507576
5.
Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results.
Ann Allergy Asthma Immunol;
131(5): 598-605.e3, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37506846
6.
Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma.
Ann Allergy Asthma Immunol;
130(6): 784-790.e5, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36906262
7.
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study.
Ann Allergy Asthma Immunol;
131(3): 343-348.e2, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37263380
8.
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
Ann Allergy Asthma Immunol;
131(5): 587-597.e3, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37619779
9.
Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
Ann Allergy Asthma Immunol;
129(4): 467-474.e3, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35728746
10.
Severe asthma exacerbation rates are increased among female, Black, Hispanic, and younger adult patients: results from the US CHRONICLE study.
J Asthma;
59(12): 2495-2508, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35000529
11.
Differing perceptions of asthma control and treatment effectiveness by patients with severe asthma and treating subspecialists in the United States.
J Asthma;
59(9): 1859-1868, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34374622
12.
Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
Ann Allergy Asthma Immunol;
127(5): 579-587.e1, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34273485
13.
Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation.
Am J Perinatol;
38(S 01): e201-e206, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32299107
14.
An expert consensus framework for asthma remission as a treatment goal.
J Allergy Clin Immunol;
145(3): 757-765, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31866436
15.
Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma.
Ann Allergy Asthma Immunol;
125(3): 294-303.e1, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32304877
16.
SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Am J Perinatol;
37(4): 421-429, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30991438
17.
Reply to Lipworth and Chan.
Am J Respir Crit Care Med;
208(2): 212-213, 2023 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37279366
18.
2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States.
Clin Infect Dis;
66(5): 665-672, 2018 02 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29029064
19.
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
Eur Respir J;
61(3)2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36997233
20.
SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Am J Perinatol;
34(1): 51-61, 2017 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27233106